IM Cannabis appoints Ronen Zalayet CEO and changes board composition
Ronen Zalayet was appointed Chief Executive Officer effective November 19, 2026, succeeding Oren Shuster. Shakked Shuster was appointed CEO of the company's Israeli subsidiary, Focus Medical Herbs Ltd., while Oren Shuster resigned as a company director and will continue serving as a director of Israeli subsidiaries. Ohad Melnik was appointed to the board subject to Israel Medical Cannabis Agency approval and was determined to be independent under Nasdaq rules. The company said the changes align with its objectiv...
Key takeaways
CEO succession: Ronen Zalayet became Chief Executive Officer effective November 19, 2026, succeeding Oren Shuster.
Board departure: Oren Shuster resigned as a director of IM Cannabis but will continue serving as a director of the company's Israeli subsidiaries.
Subsidiary leadership: Shakked Shuster became CEO of Focus Medical Herbs Ltd., the company's Israeli medical cannabis subsidiary.
Board appointment: Ohad Melnik was appointed to the board subject to Israel Medical Cannabis Agency approval, filling the vacancy from Einat Zakariya's September 2026 resignation, and the board determined he qualifies as an independent director under Nasdaq listing rules.
Strategic framing: the company stated the leadership changes align with its objective of evaluating technology-driven businesses beyond its core medical cannabis operations.
Source: leadership and board disclosures were filed in a Form 6-K filed November 20, 2026, via Exhibit 99.1 (the linked primary source
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow IMCC in real time
Get material earnings, filing, IR, and earnings-call alerts by email.